spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  growth hormone deficiency 

 HSMN NewsFeed - 27 Apr 2020
JCR Pharmaceuticals announces Completion of Acquisition of ArmaGen, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Nov 2019
Levo Therapeutics Receives Fast Track Designation From FDA for Intranasal Carbetocin for the Treatment of Prader-Willi Syndrome
Biopharmaceuticals Neurology Drug Delivery FDA
 HSMN NewsFeed - 8 Nov 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jan 2019
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Oct 2018
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Aug 2018
AbbVie Announces IMBRUVICA(R) (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jun 2018
IMBRUVICA(R) (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 May 2018
IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2017
New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jan 2017
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Sep 2016
AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA(R)) for Treatment of Marginal Zone Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jun 2016
AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA(R)) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condition with Limited Treatment Options
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2016
U.S. FDA Expands IMBRUVICA(R) (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Feb 2016
Versartis Reports Confirmatory Top-Line Two-Year Data from Ongoing Extension Study of Somavaratan in GHD Children
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 13 Nov 2015
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Dec 2014
Ascendis Pharma A/S Completes $60 million Oversubscribed Series D Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 23 Jun 2014
Versartis Appoints Endocrinologist Bert Bakker, MD, PhD, as Senior Vice President, Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 May 2014
Aeterna Zentaris Selects Charleston, S.C. as New Location for its North American Business and Global Commercial Operations
Biopharmaceuticals
 HSMN NewsFeed - 26 Mar 2014
Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN(R) In Very Young Children Born Small For Gestational Age
Biopharmaceuticals
 HSMN NewsFeed - 18 Feb 2014
Versartis Secures $55 Million in Series E Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 15 Jan 2013
Versartis Closes $25 Million Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Jun 2012
EMD Serono, Inc. Strengthens Leadership Teams with New Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Feb 2011
Versartis Completes $21 Million Series B Financing
Biopharmaceuticals Endocrinology Venture Capital
 HSMN NewsFeed - 14 Apr 2010
Paul Westberg Joins Versartis as Senior Vice President, Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Dec 2009
Aeterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 29 Jun 2009
Teva and Antares Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin(R) (Human Growth Hormone)
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 2 Jun 2009
Versartis, Inc. Completes Series A Funding of $11 Million [EUR 7.9 M] in a Joint Venture Between Index Ventures and Amunix, Inc.
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Nov 2008
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Nov 2008
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 23 Jan 2008
The American Association of Clinical Endocrinologists (AACE) Strongly Supports the FDA in Its Concerns Regarding the Marketing and Use of So-Called Bio-Identical Hormones
Biopharmaceuticals. FDA
 HSMN NewsFeed - 21 Sep 2007
Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Jul 2007
Endocrinologists Welcome FDA Avandia Recommendation
Biopharmaceuticals Endocrinology Cardiology FDA
 HSMN NewsFeed - 10 Jul 2007
Tercica Announces Agreement with Genentech for Worldwide Growth Hormone and IGF-1 Combination Product Development and Commercialization
Biopharmaceuticals
 HSMN NewsFeed - 1 Jun 2007
FDA Approves Norditropin(R)for Treatment of Short Stature Associated with a Rare Genetic Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 May 2007
Statement From the American Association of Clinical Endocrinologists Regarding The New England Journal of Medicine Article, "Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes"
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 2 Apr 2007
Pharmacia Subsidiaries Reach $34.7 Million Settlement with DOJ; Resolve Allegations of Improper Activities Prior to Acquisition by Pfizer
Biopharmaceuticals Litigation
 HSMN NewsFeed - 12 Mar 2007
Cangene receives an approvable letter from the FDA for human growth hormone
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Mar 2007
Litigation Settlement Reached Between Tercica, Genentech and Insmed
Biopharmaceuticals Litigation
 HSMN NewsFeed - 30 Jan 2007
Merck Serono Launches easypod(R), First Electronic Growth Hormone Injection Device
Biopharmaceuticals Devices Drug Delivery
 HSMN NewsFeed - 20 Dec 2006
Altus Pharmaceuticals Enters into Exclusive Strategic Collaboration with Genentech to Develop and Commercialize Products for Growth Hormone Deficient Patients
Biopharmaceuticals Licensing
 HSMN NewsFeed - 26 Sep 2006
Government Approves Lilly's Medicare Part D Patient Assistance Program
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Jun 2006
Altus Pharmaceuticals Announces Positive Results from Phase II Study in Growth Hormone Deficient Patients with Once-Per-Week Growth Hormone
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 32

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 32 additional stories matching:
growth hormone deficiency
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!